Fidelis Capital Partners LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 78.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,993 shares of the biopharmaceutical company's stock after purchasing an additional 10,099 shares during the quarter. Fidelis Capital Partners LLC's holdings in Bristol Myers Squibb were worth $1,402,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $25,000. Park Square Financial Group LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $26,000. Transce3nd LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $28,000. Global Wealth Strategies & Associates grew its position in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Bristol Myers Squibb in the 1st quarter valued at $31,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Bristol Myers Squibb Stock Performance
Shares of NYSE:BMY traded down $1.61 during midday trading on Friday, hitting $46.91. The stock had a trading volume of 13,670,701 shares, compared to its average volume of 12,845,758. The company has a market capitalization of $95.47 billion, a PE ratio of 17.57, a P/E/G ratio of 2.43 and a beta of 0.36. The stock has a 50 day moving average price of $47.58 and a two-hundred day moving average price of $53.35. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a 1 year low of $39.93 and a 1 year high of $63.33.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the business earned ($4.40) earnings per share. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 92.88%.
Insider Activity at Bristol Myers Squibb
In related news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president directly owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on BMY shares. UBS Group dropped their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, Morgan Stanley lowered their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $57.69.
Read Our Latest Research Report on BMY
About Bristol Myers Squibb
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
See Also
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
